The round included lead investor Three Arch Partners and returning investors Versant Ventures and De Novo Ventures.
Laurent Schaller, president and CEO of Benvenue Medical, said: “This financing will allow us to expand our product development programs, obtain additional regulatory approvals, and gain clinical experience with our minimally invasive spinal products.”